Candida krusei infections and fluconazole therapy

Area of Science:

• Medical Mycology
• Antimicrobial Resistance
• Infectious Diseases

Background:

• Mucosal fungal infections are common, primarily caused by Candida species.
• Candida albicans is a well-known pathogen, but non-albicans species like Candida krusei are emerging threats.
• Compromised hosts are particularly susceptible to invasive fungal infections.

Purpose of the Study:

• To investigate the increasing prevalence and resistance of non-albicans Candida species, specifically Candida krusei.
• To examine the role of fluconazole use in the rise of Candida krusei as a significant pathogen.
• To assess the prophylactic and therapeutic efficacy of fluconazole against fluconazole-resistant Candida krusei.

Main Methods:

• Review of existing human and animal studies on fluconazole efficacy and Candida resistance.
• Analysis of clinical data on the prevalence of non-albicans Candida infections.
• Microbiological studies evaluating fluconazole susceptibility in Candida krusei isolates.

Main Results:

• Candida krusei demonstrates increasing resistance to fluconazole.
• Prophylactic and therapeutic failures of fluconazole against Candida krusei have been documented.
• Widespread fluconazole use, particularly in HIV-infected individuals, is implicated in this resistance phenomenon.

Conclusions:

• Emergence of fluconazole resistance in Candida krusei poses a significant clinical challenge.
• Indiscriminate use of fluconazole may accelerate the development of azole resistance across Candida species.
• Alternative antifungal strategies and judicious use of fluconazole are warranted to combat rising resistance.